 |
市場調查報告書
商品編碼
2008034
皮膚纖維化（SF）治療市場：依藥物類型、給藥途徑、適應症、通路和地區分類。Skin Fibrosis Treatment Market, By Drug Type, By Route of Administration, By Application, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
2026年皮膚纖維化（SF）治療市場規模估計為7.96億美元，預計到2033年將達到12.67億美元。預計從2026年到2033年，該市場將以6.9%的複合年成長率成長。
| 報告範圍 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2025 | 2026年市場規模： | 7.96億美元 |
| 歷史數據時期： | 2020年至2024年 | 預測期： | 2026年至2033年 |
| 2026年至2033年預測期間的複合年成長率： | 6.90% | 2033年市場規模預測： | 12.67億美元 |
皮膚纖維化（SF）常見於嗜酸性粒細胞肌痛症候群、黏液瘤樣硬化症（丘疹性粘液瘤病）和硬化性水腫患者。纖維化通常是由於持續接觸化學物質或創傷損傷表皮和真皮所致。其特徵是真皮和皮下組織中纖維結締組織增生，常伴隨持續性發炎。纖維化通常是由於反覆接觸化學物質或創傷導致表皮或真皮損傷所致。真皮中纖維結締組織增生是其特徵之一。系統性硬皮症（SSc，也稱為硬皮症）會導致許多其他器官發生纖維化，其主要症狀是皮膚纖維化。這種纖維化是不可逆的，但目前已有的藥物可以在一定程度上進行治療。真皮纖維化是創傷治療過程中病理反應的結果，表現為皮膚過度疤痕形成。硬皮症、腎源性纖維皮症、混合性結締組織疾病、硬皮症混合性水腫、硬皮症水腫和嗜酸性粒細胞筋膜炎只是眾多纖維性皮膚病中的幾種。
市場動態
預計在預測期內，皮膚纖維化（SF）治療領域的最新進展將推動全球皮膚纖維化（SF）治療市場的成長。例如，Springer Nature 於 2017 年 12 月發表的數據顯示，新的治療策略在皮膚纖維化（SF）的治療中展現出令人鼓舞的成果。這些治療方法包括使用單株抗體的分子標靶療法。利妥Rituximab（抗CD20單株抗體）和托珠單抗（拮抗介白素-6 (IL-6) 受體抗體）均已報告具有良好的臨床療效。
本次調查的主要特點。
- 本報告對全球皮膚纖維化（SF）治療市場進行了詳細分析，提出了以 2025 年為基準年，預測期（2026-2033 年）的市場規模和復合年成長率（%）。
- 本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
- 此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
- 本報告根據以下參數對全球皮膚纖維化（SF）治療市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
- 透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
- 本報告面向該產業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 透過分析全球皮膚纖維化（SF）治療市場中使用的各種策略矩陣，相關人員將能夠更輕鬆地做出決策。
目錄
第1章：研究目標與前提條件
- 研究目標
- 前提
- 簡稱
第2章 市場範圍
- 報告摘要
- 市場定義和範圍
- 執行摘要
- Coherent Opportunity Map（COM）
第3章：市場動態、監管與趨勢分析
- 市場動態
- 促進因素
- 阻礙因素
- 市場機遇
- 影響分析
- 市場趨勢
- 近期趨勢
- 收購與合作方案
- 技術概述
- 法規環境
- 價格分析
- PEST分析
第4章 全球皮膚纖維化（SF）治療市場：依藥物類型分類，2020-2033年
- 概述
- 皮質類固醇
- 抗纖維化藥物
- 免疫療法藥物
- 其他（免疫抑制劑）
第5章 全球皮膚纖維化（SF）治療市場：依給藥途徑分類，2020-2033年
- 概述
- 口服
- 腸外
- 其他（外部用途）
第6章 全球皮膚纖維化（SF）治療市場：依適應症分類，2020-2033年
- 概述
- 局部硬皮症
- 嗜酸性粒細胞筋膜炎
- 硬化性黏液性水腫（丘疹丘疹性黏液囊腫）
- 水腫性硬化症
第7章 全球皮膚纖維化（SF）治療市場：依通路分類，2020-2033年
- 概述
- 醫院藥房
- 零售藥房
- 網路藥房
第8章 全球皮膚纖維化（SF）治療市場：按地區分類，2020-2033年
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 北非
- 中非
- 南非
第9章 競爭情勢
- Pharmaxis
- Jubilant Cadista
- Horizon Pharma USA
- Pfizer
- Sanofi
- F. Hoffmann-La Roche
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
第10章
- 調查方法
- 關於本公司
簡介目錄
Product Code: CMI5255
Skin Fibrosis Treatment Market is estimated to be valued at USD 796 Mn in 2026 and is expected to reach USD 1,267 Mn by 2033, growing at a compound annual growth rate (CAGR) of 6.9% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 796 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 6.90% | 2033 Value Projection: | USD 1,267 Mn |
Skin fibrosis generally occurs in patients who suffer from eosinophilia-myalgia syndrome, scleromyxedema (papular mucinosis) and scleredema. Fibrosis frequently develops as a result of continuous chemical exposure or trauma that causes epidermal or dermal harm. It is characterized by an increase of fibrous connective tissues in the dermis or subcutis and frequently goes hand in hand with persistent inflammation. Fibrosis frequently develops as a result of epidermal or dermal damage brought on by repeated chemical exposure or trauma. An increase in fibrous connective tissues in the dermis is one of its defining features. Systemic sclerosis (SSc also known as scleroderma), which also causes fibrosis in a number of other organs, is characterized by the primary symptom of skin fibrosis. Although, this fibrosis cannot be reversed, it can be treated to some extent using currently available drugs. Dermal fibrosis, which results from a pathologic reaction to wound healing, is excessive skin scarring. Scleroderma, nephrogenic fibrosing dermopathy, mixed connective tissue disease, scleromyxedema, scleredema, and eosinophilic fasciitis are only a few of the many fibrotic skin illnesses that exist.
Market Dynamics
The rise in recent advances in treatment for the skin fibrosis is expected to drive the global skin fibrosis treatment market growth over the forecast period. For instance, in December 2017, according to the data published by the Springer Nature, the new treatment strategy has shown promising results in the treatment of skin fibrosis. The treatment involves the molecular targeting therapy with monoclonal antibody. The positive clinical outcomes had been reported in rituximab (an anti-CD20 antibody) and the tocilizumab (an anti-interleukin-6 (IL-6) receptor antibody).
Key features of the study
- This report provides an in-depth analysis of the global skin fibrosis treatment market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global skin fibrosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pharmaxis, Jubilant Cadista, Horizon Pharma USA, Pfizer, Sanofi, F. Hoffmann-La Roche, Boehringer Ingelheim, , Bristol-Myers Squibb Company
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global skin fibrosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global skin fibrosis treatment market
Skin Fibrosis Treatment Market Segmentation
- By Drug Type Insights (Revenue, USD Mn, 2020 - 2033)
- Corticosteroids
- Antifibrotic Drugs
- Immunotherapy Drugs
- Other (Immunosuppressant)
- By Route of Administration Insights (Revenue, USD Mn, 2020 - 2033)
- Oral
- Parenteral
- Other (Topical)
- By Application Insights (Revenue, USD Mn, 2020 - 2033)
- Localized forms of scleroderma
- Eosinophilic fasciitis
- Scleromyxedema (papular mucinosis)
- Scleredema
- By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region Insights (Revenue, USD Mn, 2020 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players in the Skin Fibrosis Treatment Market
- Pharmaxis
- Jubilant Cadista
- Horizon Pharma USA
- Pfizer, Sanofi
- Hoffmann-La Roche
- Boehringer Ingelheim
- Bristol-Myers Squibb Company
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Application
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
4. Global Skin Fibrosis Treatment Market, By Drug Type, 2020 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
- Corticosteroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Antifibrotic Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Immunotherapy Drugs
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Other (Immunosuppressant)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
5. Global Skin Fibrosis Treatment Market, By Route of Administration, 2020 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Other (Topical)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
6. Global Skin Fibrosis Treatment Market, By Application, 2020 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
- Localized forms of scleroderma
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Eosinophilic fasciitis
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Scleromyxedema (papular mucinosis)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Scleredema
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
7. Global Skin Fibrosis Treatment Market, By Distribution Channel, 2020 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2020 - 2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2020-2033, (USD Mn)
8. Global Skin Fibrosis Treatment Market, By Region, 2020 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2020-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2033, (USD Mn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Pharmaxis
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Jubilant Cadista
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Horizon Pharma USA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
